Introduction
In nonmyeloablative hematopoietic cell transplantation (HCT), chimerism studies are routinely recommended to assess donor engraftment and to detect early signs of graft rejection.
1,2 The role of serial chimerism studies, especially leukocyte subset studies, using sensitive molecular markers to monitor recipients of myeloablative HCT is less well defined. A retrospective analysis of adult patients with ALL who received myeloablative transplants at a single center, using either related or unrelated donors, was performed to determine if chimerism studies done approximately 80 days after transplantation were predictive of transplant outcome.
Materials and methods
A total of 89 patients with ALL who were transplanted between January 1998 and December 2004 and had chimerism studies performed 2-3 months after transplantation were included in this study. Informed consent was obtained from all patients, using forms approved by the Institutional Review Board of the Fred Hutchinson Cancer Research Center. Of them, 78 patients had B-cell ALL, 8 had T-cell ALL and 3 had no phenotyping data. At diagnosis, 30 patients had Philadelphia chromosomepositive ALL, 19 had normal cytogenetics, 27 had other clonal cytogenetic abnormalities and 13 had no cytogenetic analyses available. Median patient age was 33.5 years (range, 18.1-55.9 years). Median duration of disease (time from date of diagnosis to date of transplant) was 8.4 months (range, 2.4-216.3 months). Disease status at the time of transplant was based on marrow morphology: 39 patients were in 1st remission, 29 were inX2nd remission and 21 were in relapse. These patient characteristics are summarized in Table 1 .
All patients received a myeloablative conditioning regimen, which included 12.0-13.5 Gy TBI. The source of stem cells was BM (n ¼ 34), G-CSF-stimulated peripheral blood (PB, n ¼ 54) or umbilical cord blood (n ¼ 1). None of the stem cell products were T-cell depleted. Of 34 related donors, 32 were HLA identical with the recipient and 2 were HLA mismatched. Of 55 unrelated donors, 37 were HLA identical with the recipient and 18 were not. HLA typing of patients and related donors included intermediate-resolution typing for HLA-A, -B, -C and DQB1 genes and high-resolution HLA-DRB1 typing. HLA typing for patients undergoing an alternative donor search included high-resolution typing for HLA-A, -B, -C and DRB1, and intermediate-resolution typing for HLA-DQB1. 3 Of the 19 patients who received adult, HLA-mismatched stem cells the degree of mismatching was as follows: a single class I or class II antigen (n ¼ 12), a single class II allele (n ¼ 4) and a single class I plus a single class II allele (n ¼ 3). The only cord blood recipient was mismatched with the donor for both HLA-A antigens based on HLA-A, -B and DRB1 typing. Of the 89 recipients 52 had donors of the same sex and 37 had opposite-sex donors. A total of 81 of the 89 patients received CYA and MTX for GVHD prophylaxis. 4 Details of the conditioning regimens and GVHD prophylaxis are summarized in Table 2 .
Donor engraftment was initially assessed, according to our standard practice, approximately 28 days after transplantation. Morphologic, conventional and molecular cytogenetic, and flow cytometric studies were performed on unfractionated BM specimens at this time point.
At a median of 77 days (range, 65-113 days) after transplantation, the 'day 28' studies were repeated and chimerism analysis was also performed. Unfractionated BM cells or PB sorted for CD3 þ T cells and CD33 þ neutrophils were studied at this later time point. Patients who had sex-mismatched donors had chimerism studies done by conventional cytogenetic analysis of metaphase chromosomes or by molecular cytogenetic techniques, that is, FISH using X and Y chromosome-specific probes. 5 Patients who had donors of the same sex had chimerism studies done by amplification and analysis of variable number tandem repeat (VNTR) or short tandem repeat (STR) polymorphisms by DNA amplification. 6 VNTR studies, performed routinely between 1998 and April 2004, involved amplification of individual VNTR loci with analysis on precast polyacrylamide gels with silver staining. 7 As of May 2004, same sex transplant pairs had chimerism studies performed by multiplex amplification of STR loci (PowerPlex 16; Promega, Madison, WI, USA) with analysis by capillary electrophoresis (ABI 3130 Â l; Applied Biosystems, Foster City, CA, USA). Both methods achieved at least 5% sensitivity as documented by external proficiency challenges. 7, 8 Depending on the relative size of the informative VNTR markers, sensitivity was as low as 0.1%, as assessed by internal mixing studies. STR analysis routinely achieved 0.5% sensitivity as assessed by mixing studies.
Disease-free survival probabilities were estimated using the Kaplan-Meier method. 9 
Results
The incidence of acute and chronic GVHD, survival, relapse and causes of death are summarized in Table 2 .
A total of 47 patients had chimerism studies performed on unfractionated BM and 58 patients had studies of fractionated PB samples (20 of the 89 patients had both BM and PB studies.) Only 2 of the 47 patients who had chimerism studies of BM had o90% donor-derived cells (82.6 and 45%, respectively) at the time of analysis. The patient with the lowest percent donor chimerism was known to be in relapse at the time the chimerism test was done. Both of these patients died o4 months after transplant from relapsed ALL. None of the 58 patients who had PB chimerism studies had o90% donor cells in the CD33 þ neutrophil fraction. There was a wider range in donor CD3
þ T-cell percentages as shown in Figure 1 . Of the 58 patients, 11 had o90% donor CD3 þ T cells, but none had o20% donor CD3 þ T cells, a level previously reported to be associated with graft loss. 1 None of the patients in this analysis experienced subsequent graft rejection. The actuarial probability of disease-free survival was not significantly different between the group of patients with o90% donor CD3 þ T cells and those withX90% donor CD3 þ T cells (62 vs 48% at 3 years, respectively, P ¼ 0.49). Similarly, there was no difference in the probability of relapse at 3 years between these two groups (38 vs 40%, respectively).
Of the 58 patients who had PB chimerism studies performed, the percentage of donor CD3 þ T cells did not correlate with the severity of acute GVHD, but only 6 of the 58 patients developed mild (grade I) acute GVHD. Similarly, stem cell source (BM vs PB), donor type (related vs unrelated), HLA matching and relapse after transplantation did not correlate with the degree of mixed chimerism in PB at the time of evaluation. These observations, however, are based on a small number of patients in each subgroup who had mixed chimerism when tested.
During the time period covered in this analysis, 23 additional adult ALL patients received myeloablative transplants, but did not have chimerism studies performed. Of them, 21 patients died early after transplantation (median day of death ¼ day 29, range ¼ 5-66 days). One patient had persistent disease after a syngeneic transplant and died on day 204 after receiving a second transplant from an unrelated donor. Of the 23 patients, 2 relapsed, on days 19 and 47, with the relapse diagnosed by morphology of the peripheral smear or marrow, respectively. None of the 22 patients had evidence of graft failure prior to death. Only 1 of these 23 patients survived at least 80 days; this patient is alive in remission47 years after HCT.
Discussion
In patients undergoing nonmyeloablative or reducedintensity HCT, chimerism analyses provide useful information regarding graft rejection and minimal residual disease. 2, 8 Serial, quantitative chimerism studies have been recommended for children with ALL after allogeneic HCT to identify those patients at high risk of relapse. 10 In general, analysis of PB cells is more useful than BM cells because lineage-specific chimerism can be determined. 1 Before the advent of FISH and PCR-based studies, the degree of donor engraftment was assessed by conventional karyotype analyses for sex-mismatched donor-recipient pairs, RBC phenotyping or Ig isotypes. 11 All of these techniques were associated with low sensitivity. FISH analysis of sex chromosomes is more quantitative than conventional cytogenetics, whereas PCR-based methodology (with VNTR or STR analyses) is not only a more sensitive technique, but also permits analysis of very small numbers of cells. The sensitivity of VNTR and STR analyses by PCR methods is estimated at 1-5%, but may be as low as 0.1% depending on the informative markers and the strength of amplification. 6, 7 The laboratory fees at this center for one chimerism study using FISH or PCR-based technology range from $600 (without cell subset isolation) to $850 (with cell subset isolation by flow cytometry).
The patient population in this retrospective analysis was fairly homogeneous, with all patients having a diagnosis of ALL, being X18 years of age and receiving myeloablative, TBI-based conditioning regimens followed by infusion of allogeneic, unmanipulated stem cells. GVHD prophylaxis was standardized with 91% of patients receiving CYA and MTX. A total of 24% of patients were in relapse at the time of transplantation, a factor that previously has been shown to be associated with a significantly increased risk of post transplant relapse. 12 A low frequency of incomplete donor chimerism was found 2-3 months after transplant. In addition, lineage-specific (CD3 þ and CD33 þ ) PB chimerism studies were not predictive of transplant outcome, leading to the recommendation that these studies not be routinely obtained in this patient population. This conclusion is in agreement with the recommendations for assessment of chimerism following myeloablative HCT for hematologic malignancies by the IBMTR/ABMTR. 1 In contrast, frequent PB chimerism studies have been recommended for children with ALL undergoing allogeneic transplantation to detect increasing mixed chimerism, allowing for early intervention with immunomodulatory therapy. 10 The patient group in this study was more heterogeneous, with results grouped from several transplant centers. Of the 165 patients 15% (25/163) received chemotherapy-only preparative regimens and 41% (67/163) received T-cell-depleted grafts. Only 1 of the 163 patients was in relapse at the time of transplant.
The disparate conclusions about the role and timing of chimerism studies in the pediatric ALL study compared to our study illustrate the importance of defining the specific patient populations for whom chimerism studies are useful in monitoring transplant outcome. The value of chimerism studies for other subgroups of patients, including those who undergo myeloablative HCT using chemotherapy-only preparative regimens, patients who receive T-cell-depleted grafts and patients who have greater degrees of HLA disparity with their donors, for example, haplo-identical transplant recipients, remains to be determined.
